ePointZero to Acquire Majority Stake in Pan-African Power Platform, Azura Power Holdings Limited

NEWS PROVIDED BY

ePointZero

Aug 31, 2026, 00:12 ET

SHARE THIS ARTICLE

The transaction marks ePointZero's entry into African power generation through a proven operating platform with immediate scale, resilient cash flows, and experienced management.

Acquisition provides Azura Power, a 752 MW pan-African independent power producer, with a committed partner and long-term capital to accelerate its growth pipeline and play a larger role in addressing the continent's power deficit.

The transaction underscores ePointZero's disciplined approach to investing in high-quality infrastructure with resilient, long-term cash flows and demand visibility. Amaya Capital, founders of Azura Power, to retain minority stake.

ABU DHABI, UAE, Aug. 31, 2026 /PRNewswire/ -- ePointZero, a global platform focused on specialized energy infrastructure and a subsidiary of 2PointZero Group, will acquire a 90% stake in Azura Power Holdings Limited ("Azura Power"), an established pan-African independent power producer (IPP).

The 461MW Azura-Edo Independent Power Plant near Benin City, Edo State, Nigeria.

Azura Power has over 750MW of operating capacity and a growth pipeline of over 1.5GW which could more than double the platform's operational capacity in the coming years. It operates critical power generation assets across Nigeria, Senegal and Mozambique, where it generates around 10% of each country's grid baseload power.

Under the transaction terms, ePointZero has partnered with Amaya Capital to establish an acquisition vehicle, through which ePointZero will acquire the respective ownership stakes of Actis and Africa50. Amaya Capital, Azura Power's founding partner, will retain a minority interest of 10%, underscoring its continued confidence in the future growth of the platform it founded in 2010. Completion of the transaction is subject to customary regulatory approvals and closing conditions.

Commenting on the transaction, HH Sheikh Zayed bin Hamdan bin Zayed Al Nahyan, Chairman of 2PointZero, said: "Reliable power is fundamental to economic growth, industrial development and long-term prosperity. This investment through ePointZero reflects our commitment to deploying long-term capital into critical infrastructure that can support that growth in key markets across Africa."

H.E. Mariam Almheiri, Vice Chair & Managing Director, 2PointZero, said: "At 2PointZero, we are building platforms that create long-term value by investing in the infrastructure shaping tomorrow's economies. As ePointZero continues to expand its global energy platform, the acquisition of Azura Power strengthens our presence in a region where energy demand, economic growth, and long-term opportunity are closely aligned. It reflects our disciplined approach to investing in businesses with strong fundamentals, local expertise, and long-term value."

Mohamed Hesham, CEO of ePointZero, said: "Azura Power brings together many of the qualities we look for in an energy platform: critical operating assets, an experienced management team and a strong position in markets with significant long-term power needs. We are acquiring a business built on nearly a decade of disciplined execution, with significant opportunity to support its continued growth as demand for reliable power infrastructure across the continent accelerates. Together with our strategic investment in Elsewedy Electric and its established industrial and EPC presence across Africa, our acquisition of Azura Power deepens ePointZero's capabilities in energy and infrastructure and positions us to pursue new opportunities across Africa's evolving energy markets."

Dave Peacock, Group CEO, Azura Power, commented: "This transaction is a significant milestone for Azura. We are proud of what our teams have built over the past ten years and the confidence shown by ePointZero is a strong endorsement of that achievement. I would like to thank our shareholders for their trust, partnership and support throughout that journey. With ePointZero now joining Amaya, Azura is well positioned to build on its strong foundations, broaden its opportunity set and accelerate its growth across Africa's energy sector."

Africa's power market is entering a period of sustained investment as population growth, urbanization and industrial development drive demand for new generation capacity. Electricity demand across the African region is expected to nearly double by 2040. Yet, electricity access across Sub-Saharan Africa remains at roughly 55% according to the World Bank, underscoring both the scale of infrastructure needs and the opportunity for long-term private capital.

Azura Power has made a steady contribution to flexible, dispatchable and sustainable power generation in Nigeria, Senegal and Mozambique as demand for reliable electricity continues to grow. It will continue to pair infrastructure investment with Power to Change - its social-impact program, supporting livelihoods and economic opportunity in the communities where it operates. Azura Power's development pipeline includes expansions at existing sites as well as additional gas and renewable projects already in progress. Alongside long-standing relationships and alignment with national utilities and governments, Azura Power's projects have also enjoyed financing and support from a range of the world's leading development finance institutions, including the World Bank, BII, DEG, DFC, FMO, IFC, MIGA and Proparco.

About ePointZero

Founded in Abu Dhabi, ePointZero is a global platform investing in specialized energy infrastructure. The company deploys capital into energy infrastructure that strengthens baseload power capacity and supports industrial growth, including pipelines, power generation, and energy storage assets. Through its operations and holdings, ePointZero plays a central role in enabling systems that power electrification, support rising global demand, and enable the next generation of digital and industrial growth. ePointZero is a subsidiary of 2PointZero Group headquartered in the UAE, strategically positioned in key energy corridors, industrial hubs and high growth markets.

About Azura Power

Azura Power is a developer, financier, acquirer and operator of Independent Power Plants ("IPPs") across Africa. Azura Power operates 752 MW of operational capacity across three assets: Azura-Edo (461 MW, Nigeria), Tobene (116 MW, Senegal) and CTRG (175 MW, Mozambique), located in three of Africa's largest natural gas reserve markets. The assets are underpinned by long-term power purchase agreements. As a leading IPP in Africa with significant experience in the gas sector and development of energy projects, Azura's mandate is to enhance and expand its operational portfolio in alignment with Africa's energy transition. Its current development pipeline of more than 1.5GW consists of gas, renewable and BESS projects across the continent.

About Amaya Capital

Amaya Capital is an African focused principal investment firm that founded Azura Power in 2010. Amaya initially developed the first publicly project financed power plant in Nigeria, in collaboration with the World Bank Group and other DFIs, from a greenfield site to one of the country's leading IPPs.  After bringing in Actis and Africa50 as co-investors, it has played a key role in the development of Azura Power into the diversified power generation platform that exists today. 

SOURCE ePointZero

21%

more press release views with 

Request a Demo

Samsung Biologics publishes prospectus for PolyPeptide public tender offer

NEWS PROVIDED BY

Samsung Biologics

Aug 31, 2026, 01:00 ET

SHARE THIS ARTICLE

Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer

Publication of offer prospectus follows pre-announcement on July 20, 2026

Largest individual shareholder committed to tender all of its PolyPeptide shares into offer

Main offer period expected to last from Sept. 15 to Oct. 12, 2026

INCHEON, South Korea and ZUG, Switzerland, Aug. 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the tender offer prospectus ("Offer Prospectus") for all publicly held registered shares of PolyPeptide Group AG ("PolyPeptide").

PolyPeptide shareholders will receive CHF 44.31 net in cash for each PolyPeptide share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium compared with the unaffected price of PolyPeptide's shares on the SIX Swiss Exchange ("SIX") as of April 10, 2026, which was the last trading day prior to the publication of the first media speculation regarding a potential acquisition of PolyPeptide. The offer price represents a premium of 11.6% compared with the volume-weighted average share price over the last 60 trading days prior to the pre-announcement on July 20, 2026.

The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that PolyPeptide's shareholders accept the offer. The recommendation is further supported by an independent fairness opinion from IFBC AG.

Draupnir Holding B.V., PolyPeptide's largest individual shareholder, who holds approximately 55.65% of the total PolyPeptide shares outstanding (excluding treasury shares), has undertaken to tender all of its shares into the offer.

The main offer period commences on Sept. 15, 2026 and is expected to end on Oct. 12, 2026 at 4 p.m. Swiss time. The offer is subject to a minimum acceptance threshold of 66⅔% on a fully diluted share count basis (excluding treasury shares), applicable regulatory approvals, and other customary conditions described in the Offer Prospectus. The Offer Prospectus and further offer documentation is available on https://samsungbiologics.com/offer.

Following the settlement of the offer Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide's shares from the SIX.

Media Contact

samsungbiologics@info.sodali.com

+44 20 7100 6451

Victoria Palmer-Moore

vpm@sodali.com

Sam Austrums

sam.austrums@sodali.com

Peter Lambie

peter.lambie@sodali.com

Contact for Institutional Investors and Retail Shareholders

polypeptide-offer@investor.sodali.com

Institutional investor hotline: +44 204 5136928

Retail investor hotline: +41 43 550 72 52

Sodali has been mandated by Samsung Biologics on behalf of Samsung Peptide as information agent in connection with this offer.

About Samsung Peptide

Samsung Peptide AG, Zug, Switzerland, is a direct subsidiary of Samsung Biologics and was established to act as the formal offeror of the offer.

About Samsung Biologics

Samsung Biologics Co., Ltd., Incheon, Republic of Korea (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries ("PolyPeptide") is a specialized contract development and manufacturing organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S., and India. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

Disclosure Notice

The Offer Prospectus, which has been published today, and additional offer documentation is available at https://samsungbiologics.com/offer.

The public tender offer is subject to customary terms and conditions as well as regulatory approvals and is currently expected to be completed by the end of 2026.

This publication does not constitute a prospectus or a similar notice according to articles 35 et seqq. and 69 of the Swiss Financial Services Act, is for information purposes only and does not constitute an offer document or an offer of securities for purchase or subscription, nor a solicitation of an offer to buy or subscribe for securities, in any jurisdiction. The terms and conditions of the tender offer are set out exclusively in the Offer Prospectus, published in accordance with applicable Swiss takeover law, including the Swiss Financial Market Infrastructure Act and the Takeover Ordinance. Investors and holders of PolyPeptide shares are advised to carefully read the Offer Prospectus, as well as all other documents relating to the tender offer, as they contain important information about the offer.

Offer Restrictions

General

The public tender offer for the registered shares with a nominal value of CHF 0.01 each of PolyPeptide as described in the documents available on this website (the "Offer") will not be made, directly or indirectly, in any country or jurisdiction in which it would be illegal or otherwise violate any applicable laws or regulations, or which would require Samsung Biologics Co., Ltd. ("Samsung Biologics"), or any of its direct or indirect subsidiaries, including Samsung Peptide to change or amend the terms or conditions of the Offer in any way, or to submit any additional filing to any governmental, regulatory or other authority, or to perform any additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any documents relating to the Offer must not be distributed in or sent to any such country or jurisdiction and must not be used for the purpose of soliciting the sale or purchase of securities of PolyPeptide by any person or entity resident or incorporated in any such country or jurisdiction. The terms and conditions of the Offer have been and/or will be published in the Offer documentation. Please visit https://samsungbiologics.com/offer for more information.

Shareholders of PolyPeptide should review the Offer Prospectus and all other Offer documents carefully. The Offer may not be accepted before the expiration of a cooling-off period of ten (10) SIX Swiss Exchange trading days (if not extended by the Swiss Takeover Board), which will run from September 1, 2026.

According to the laws of Switzerland, PolyPeptide shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular in case a competing offer for PolyPeptide shares is launched.

United States of America

The Offer will be made for the registered shares of PolyPeptide, a Swiss company whose shares are listed on the SIX, and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.).

The Offer will be made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemption provided by Rule 14d-1(c) under the U.S. Exchange Act (the Tier I Exemption) and Rule 14e-5(b)(10) under the U.S. Exchange Act and any exemptions that may be granted by the U.S. Securities and Exchange Commission (SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws.

Any financial statements or figures included or referenced in the Offer Prospectus have been or will be prepared in accordance with the applicable accounting standards of, or recognized in, Switzerland and/or the Republic of Korea, which may not be comparable to the financial statements of U.S. companies.

In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Samsung Biologics and its subsidiaries (including Samsung Peptide) and affiliates or their respective nominees or brokers (acting as agents for Samsung Peptide) may from time to time after the date of the Offer Prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase PolyPeptide shares or any securities that are convertible into, exchangeable for or exercisable for PolyPeptide shares from their holders who are willing to sell them outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities laws, rules and regulations, including Rule 14e-5 under the U.S. Exchange Act (subject to the exemption provided by Rule 14e-5(b)(10) under the U.S. Exchange Act). Any such purchases will not be made at prices higher than the offer price or on terms financially more favorable than those offered pursuant to the Offer, unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on https://samsungbiologics.com/offer if and to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to PolyPeptide and, subject to applicable Swiss and U.S. securities laws, rules and regulations, including Rule 14e-5 under the U.S. Exchange Act (subject to the exemption provided by Rule 14e-5(b)(10) under the U.S. Exchange Act), the financial advisor to Samsung Biologics and its subsidiaries (including Samsung Peptide) and affiliates may also engage in ordinary course trading activities in securities of PolyPeptide, which may include purchases or arrangements to purchase such securities.

It may be difficult for holders of PolyPeptide shares in the U.S. (U.S. Holders) to enforce their rights and any claim they may have arising out of U.S. securities laws, since Samsung Peptide and PolyPeptide are located in non-U.S. jurisdictions, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. Holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.

The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of PolyPeptide is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer.

Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer; (b) passed upon the merits or fairness of the Offer; or (c) passed upon the adequacy or accuracy of the disclosure in this Offer Prospectus. Any representation to the contrary is a criminal offence in the U.S.

U.S. Holders are encouraged to consult with their own legal (including with respect to Swiss law), financial and tax advisors regarding the Offer.

United Kingdom

The communication of this Offer Prospectus is not being made by, and has not been approved by, an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended. In the United Kingdom (U.K.), this communication and any other documents relating to the Offer is/will be directed only at persons (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Order), (ii) falling within article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). No communication in respect of the Offer must be acted on or relied on in the U.K. by persons who are not relevant persons. The Offer and any investment or investment activity to which this communication relates is / will be available in the U.K. to relevant persons only and will be engaged in only with relevant persons.

Australia, Canada and Japan

The Offer will not be addressed to shareholders of PolyPeptide whose place of residence, seat or habitual abode is in Australia, Canada, or Japan, and such shareholders may not accept the Offer.

Forward Looking Statements

This announcement contains forward-looking statements that reflect Samsung Biologics' and Samsung Peptide's current expectations and views of future events. These statements can often be identified by terms such as "expect," "intend," "plan," "anticipate," "target," "believe," "will" and similar expressions. They include, among other things, statements relating to the expected timing, structure and completion of the tender offer; the anticipated benefits and synergies of the proposed transaction; and the future business, operations, financial performance and strategy of Samsung Biologics, Samsung Peptide and PolyPeptide.

SOURCE Samsung Biologics

21%

more press release views with 

Request a Demo

SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring USA - English

NEWS PROVIDED BY

SIBIONICS

Aug 31, 2026, 00:19 ET

SHARE THIS ARTICLE

MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with Credentialled Diabetes Educators (CDEs), the company brought together advanced technology, clinical evidence and real-world perspectives.

At IDF-WPR 2026 & ADC 2026 & Metabolic Diseases 2026, we shared how GS3 is bringing AI into everyday glucose management — from easier meal logging and food analysis to smarter insights into glucose trends.

The technology story behind GS3 begins far beyond glucose monitoring. SIBIONICS' work in brain–computer interfaces includes a retinal prosthesis designed to provide limited visual perception for people with profound vision loss caused by outer retinal degenerative diseases, such as retinitis pigmentosa. These high-complexity systems require precise, stable biosensing and robust signal processing. SIBIONICS has translated this high-threshold engineering into a more widely accessible medical technology: continuous glucose monitoring. The same platform capability now supports GS3, a factory-calibrated, 14-day CGM sensor with a 2.9 mm profile, designed to provide reliable monitoring with a low on-body burden.

At the symposium "Beyond Glucose: The Integrated Future of CGM, CKM, and AI in Diabetes," jointly hosted by SIBIONICS and Air Liquide Healthcare, session chair Professor Sofianos Andrikopoulos, Group CEO of the Australian Diabetes Society, brought together three perspectives. Professor David O'Neal, University of Melbourne and Deputy Director of the Australian Centre for Accelerating Diabetes Innovations, reviewed emerging clinical evidence for continuous glucose and ketone monitoring. Associate Professor Shannon Lin, a diabetes and nutrition specialist at the University of Technology Sydney, examined how CGM can move beyond data visibility toward personalised, predictive and actionable support. Professor Wei Qiang, Associate Chief Physician and Deputy Director of Endocrinology and Metabolism at the First Affiliated Hospital of Xi'an Jiaotong University, outlined an integrated, AI-driven ecosystem connecting trusted sensing, context and learning.

Throughout the congress, physicians and diabetes educators visited the SIBIONICS booth to experience GS3 and discuss its glucose-management capabilities. In anonymised interviews, CDEs described the sensor as small, light, comfortable and easy to set up. They saw particular potential in AI-supported spike detection, easier meal logging and food analysis that connects glucose trends with meal context. Their feedback also highlighted the importance of personalisation, clear carbohydrate estimates and clinically useful event timelines—reinforcing that AI should extend education and decision support, not replace professional care.

Looking ahead, SIBIONICS plans to integrate its sensing platform with continuous ketone monitoring, insulin delivery, AI and other diabetes technologies. The goal is a richer, reliable and efficient ecosystem that shortens the path from data to understanding—and from understanding to action.

21%

more press release views with 

Request a Demo

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management USA - English

NEWS PROVIDED BY

Huawei

Aug 31, 2026, 00:23 ET

SHARE THIS ARTICLE

MUNICH, Aug. 31, 2026 /PRNewswire/ -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and fitness, offering an exclusive sneak peek at its next-generation ambulatory blood pressure monitor, the HUAWEI WATCH D3, ahead of its official launch at the Huawei Innovative Product Launch in Munich on 2 September. Bridging cutting-edge academic research with everyday consumer technology, Huawei continues to demonstrate its commitment to open collaboration, connecting pioneering research with products that reshape people's daily lives.

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

A Legacy of Persistence, A Leap Forward

Huawei's journey in blood pressure monitoring technology traces back to 2014, when the company first ventured into the sports and health domain. Over the past decade, Huawei has steadily advanced wearable health monitoring technologies to drive the evolution of the industry, from dynamic heart rate monitoring and SpO₂ tracking to ECG collection, and ultimately to blood pressure measurement.

In 2021, Huawei launched its first wrist-based ambulatory blood pressure recorder, the HUAWEI WATCH D. This device brought medical-grade blood pressure measurement capabilities to people's wrists for the first time, securing medical device certification in multiple countries and regions, including China and the European Union. In 2024, the HUAWEI WATCH D2 was officially released, introducing 24-hour ambulatory blood pressure monitoring and redefining blood pressure management.

In 2026, Huawei is set to unveil its latest achievement in blood pressure health—the next-generation HUAWEI WATCH D series. As the latest wrist-based ambulatory blood pressure recorder, the HUAWEI WATCH D3 achieves further breakthroughs across more blood pressure measurement scenarios while delivering more comprehensive health protection.

Lightweight Design, Professionalism Meets Style

To enhance comfort during extended wear, the HUAWEI WATCH D3 features further refinements in device thickness and strap weight. It will be available in three fashionable colour options inspired by "nature's healing"—designed not only for comfort but also as a stylish everyday accessory, seamlessly blending in with diverse lifestyles and sports scenarios.

Broader Scenarios, Richer Health Insights

The HUAWEI WATCH D3 ensures accurate blood pressure measurement at elevated heart rates. It accurately records blood pressure data before and after exercise, provides recommendations on appropriate exercise intensity, and helps users develop good fitness habits. Furthermore, the HUAWEI WATCH D3 has been certified by CE MDR in the European Union, with its certification scope covering single blood pressure measurements, ambulatory blood pressure monitoring, and pre- and post-exercise blood pressure measurements. Newly added features include blood pressure measurement reminders for high-altitude environments and sudden temperature changes, ensuring users never miss a critical monitoring check.

Beyond its core blood pressure monitoring capabilities, the HUAWEI WATCH D3 also offers richer Health Glance metrics and health studies, alongside continuous improvements in sleep and emotional wellbeing tracking[1]. Further details on specific applications will be announced in due course.

Stay tuned to Huawei's official channels for information on the official launch date, pricing, and full specifications of the HUAWEI WATCH D3.

[1] The data collected by Health Glance features and health studies is for reference only, and should not be used for diagnosis or treatment.

21%

more press release views with 

Request a Demo

Eluvio Tapped for Cricket TV: New Direct-to-Consumer Streaming Service for Live and Archive Coverage to Fans Across the Globe

NEWS PROVIDED BY

Eluvio, Inc.

Aug 31, 2026, 00:02 ET

SHARE THIS ARTICLE

New Direct-to-Consumer Streaming Service: New streaming service from Cricket Australia (tv.cricket.com.au), built upon Eluvio's Content Fabric and AI Video Intelligence, is now available for early access with full commercial launch later this year

Unified Platform for Live and VOD Streaming: Fans can watch ultra-quality live and VOD matches, recent highlights and replays, original documentaries, and archival content enabled by new hyper-efficient Fabric platform

Extends use of Eluvio AI in Archive: Cricket TV builds on Cricket Australia's use of Eluvio's frame-accurate AI services to ingest, process, and compose from its deep match archive  

BERKELEY, Calif., Aug. 31, 2026 /PRNewswire/ -- Ahead of IBC Show 2026, Eluvio today announced that Cricket Australia has launched Cricket TV, a new direct-to-consumer streaming service built upon Eluvio's Content Fabric and AI Video Intelligence, extending Cricket Australia's live and archival programming to fans beyond its existing broadcast markets across the globe. Cricket TV is now available for early access with full commercial launch of the service expected later this year at https://tv.cricket.com.au.

Eluvio Tapped for Cricket TV

"We're excited to extend our partnership with Eluvio as we continue to grow Cricket TV and make Australian cricket more accessible to fans around the world," said Dan Allan, Senior Content Manager, Broadcast at Cricket Australia. "Cricket TV brings live matches and some of the best moments from our archive together in one place for fans around the world. Eluvio has been a fantastic partner throughout the process, helping us deliver a high-quality viewing experience while giving us the flexibility to keep evolving the platform. During the early access period, Cricket TV has already reached viewers in more than 40 countries, highlighting the strong global interest in Australian cricket."

"We're honored to have extended our relationship with Cricket Australia, not only to serve their fans with live matches, but also to serve as a model for other sports organizations looking for the most efficient and cost-effective way to deliver protected sports content with the quality today's global viewers deserve," said Michelle Munson, CEO and Co-founder, Eluvio. "With one Fabric, sports rights holders can unlock dark markets and monetize live and VOD and leverage frame-accurate inline AI, without file copies— all at a fraction of legacy costs while retaining full control of their customers' experience and viewer analytics."

A Unified Platform for Streaming and AI Video Intelligence

Cricket TV provides a white-label browser, mobile, and connected TV application to its viewers built using the Eluvio Media Wallet platform (full turnkey OTT Suite). Cricket TV relies on Eluvio's Content Fabric to receive live matches or archival source feeds and dynamically ingests, transcodes, publishes and generates just-in-time streaming output directly to viewers. Streaming is provided at full source resolution, including HD and 4K, with dynamic automatic adaptation to the user's available bandwidth with low latency HLS/DASH delivery, unlimited multi-view, "zero-copy" live-to-VoD and fast DVR playback. The platform also provides subscriptions, pay-per-view, and/or ad-supported monetization, while providing end-to-end content security and anti-piracy protection including strong encryption, DRM, forensic watermarking, and dynamic authorization per-offering including geo blocking and rights control. All features are built-in allowing for a hyper-efficient, tamper-proof distribution, fast and easy purchasing, and on-screen authenticity proofs for the viewer.

In addition, the Eluvio Video Intelligence Editor (EVIE) and AI-assisted tools provide frame-accurate, in-line analysis, indexing, and search, composition, and transformation such as live vertical video, all without file copies or re-transcoding. Finally, Eluvio Content Analytics provides complete transparency of source-to-viewer audience, QoS, and sales analytics. Full details about Eluvio's technical capabilities and benefits can be found at https://eluv.io

Eluvio at IBC Show 2026

During IBC Show 2026 at the RAI Amsterdam, Eluvio will highlight its work with Cricket Australia and showcase the full capabilities of the Content Fabric and Eluvio AI in Hall 8, Stand 8.MS5, and in the Future Tech Zone, Hall 14, Stand 14.A58, September 11–14, 2026. Eluvio's CEO and co-founder, Michelle Munson, will also speak on the Future Tech Zone stage on Sunday, September 13 from 2:00–2:15 p.m. Registration for one-on-one meetings and information about Eluvio's on-site keynote demonstrations at IBC is available at https://ibc.eluv.io.

About Eluvio

Eluvio (https://eluv.io) is solving the generational problems of video over the Internet with its Content Fabric Protocol — transforming the distribution and monetization of premium video and digital media in contrast to legacy cloud workflows and CDNs. Eluvio serves Amazon Studios/MGM, Cricket Australia, European Professional Club Rugby, FOX, SONY, Telstra Broadcast Services, UEFA, United Rugby Championship, Warner Bros., WPALiveTV, WWE, and others. Led by Michelle Munson and Serban Simu, founders and inventors of Aspera, and based in Berkeley, California. Eluvio holds  more than 15 issued US patents and has won multiple NAB Streaming Product of the Year awards, the Seicon Grand Prize, the Hollywood Professional Association Engineering Excellence Award, and other industry honors. On X: @EluvioInc | LinkedIn: linkedin.com/company/eluv-io

About Cricket Australia

Cricket Australia is the national governing body for the sport of cricket in Australia, responsible for the game at the international, domestic, and grassroots levels, including the Australian Men's and Women's national teams and domestic competitions such as the Sheffield Shield, the WNCL, and the KFC BBL and WBBL. More information is available at cricket.com.au.

SOURCE Eluvio, Inc.

21%

more press release views with 

Request a Demo

LONGWELL EC FanWall Technology Reduces CRAH Fan Energy 38% for Next-Generation AI Data Centers

NEWS PROVIDED BY

Ningbo Longwell Electric Technology Co., Ltd. (LONGWELL)

Aug 31, 2026, 00:08 ET

SHARE THIS ARTICLE

Top-3 global precision cooling OEM moved from spec lock to mass production in 90 days; CRAH system PUE contribution improved from a 1.42 baseline to 1.28.

NINGBO, China, Aug. 31, 2026 /PRNewswire/ -- LONGWELL (Ningbo Longwell Electric Technology Co., Ltd.), a global EC fan and motor manufacturer founded in 1990, today released its AI-Era Data Center Cooling Pack. At its core, the LWBE3G plug-fan platform enables FanWall arrays that cut CRAH fan energy by 38%.

LONGWELL EC FanWall Technology

Working with a top-3 global precision cooling OEM, LONGWELL delivered 12 engineering samples in 35 days and passed DV/PV at 100% first time. The incumbent European supplier had quoted 14 months of development plus six months of ramp while LONGWELL used 90 days from spec lock to mass production. Recorded outcomes: 38% fan energy reduction, 6.5 dB(A) lower noise, CRAH system PUE contribution from 1.42 to 1.28, and zero field failures. The customer's first PO was 1,500 units; 2025 deliveries exceeded 80,000 units under a 2025–2027 framework agreement with a 60,000-unit annual minimum.

As AI compute scales, rack heat density has jumped from 15-20 kW to 60-100 kW in two years, with next-generation platforms pushing beyond 100 kW. LONGWELL covers the full airflow chain: LWBE3G EC plug fans for CRAH/CRAC, LWAE3G EC axial fans for condensers and cooling towers, with Modbus control, N+1 automatic failover, and optional bearing vibration sensors giving 30–90 days of end-of-life warning. The full 28-page Data Center Cooling Pack is available at https://www.longwellfans.com/solutions/data-center-cooling/ 

"AI compute has redefined data center cooling," said Bruce Li, Founder & CEO of LONGWELL. "Above 60 kW per rack, the fan stage is no longer a component choice — it decides whether a PUE target is reachable at all."

About LONGWELL: Founded in 1990 in Yuyao, Ningbo, China, LONGWELL designs and manufactures EC and AC fans and motors for HVACR and industrial applications, exporting to more than 30 countries with annual data center fan capacity exceeding 120,000 units. Learn more at longwellfans.com.

Performance figures reflect a specific project and duty point; final selection should be confirmed by duty point, voltage/control, mounting and project validation. Comparative timelines and energy figures refer to the equipment replaced in that project and imply no affiliation or endorsement.

21%

more press release views with 

Request a Demo

31.08.2026 – 05:00

WDR Newsroom

Kokainkonsum in NRW: Krankenhausaufenthalte steigen, Delikte auf Rekordniveau.

Köln (ots)

Immer mehr Menschen in Nordrhein-Westfalen müssen nach Kokainkonsum im Krankenhaus behandelt werden. Gleichzeitig hat sich die Zahl der Straftaten im Zusammenhang mit Kokain und Crack hier in den letzten zehn Jahren verdreifacht.

Das zeigt eine aktuelle Datenerhebung vom Radiosender 1LIVE. Datenjournalistinnen und -journalisten werteten die Polizeiliche Kriminalstatistik vom LKA und von 12 Kreispolizeibehörden in NRW aus. Zusätzlich analysierten sie die Daten vom Land NRW zu Krankenhausaufenthalten nach Kokainkonsum.

Kokain führte 2024 eher in großen Städten in NRW zur Behandlung im Krankenhaus.

Die meisten Krankenhausaufenthalte wegen Kokain pro 100.000 Einwohner verzeichneten Hagen, Köln und Dortmund. Besonders stark sind die Anstiege in Duisburg, wo sich die Fälle in zehn Jahren verachtfacht haben, und in Krefeld und Leverkusen, wo sie sich versiebenfacht haben. Die einzige Ausnahme bildet Herford. Dort sind die Zahlen rückläufig.

Die steigende Zahl der Krankenhausaufenthalte wegen Kokain kann unterschiedliche Ursachen haben. Eine davon ist aus Sicht von Dr. Barbara Schneider, Chefärztin der Abteilung Abhängigkeitserkrankungen, Psychiatrie und Psychotherapie an der LVR-Klinik in Köln, eine höhere Verfügbarkeit der Droge. “Die Substanz muss immer verfügbar sein, sonst kann man nicht von ihr abhängig werden.", so Schneider.

Auch Felix Strobach, Bereichsleiter der Jugendsuchtberatung der Drogenhilfe Köln, beobachtet einen Wandel beim Konsum: “Das ist mittlerweile eine ganz normale Partydroge oder auch in vielen Fällen eine ganz normale Alltagsdroge.“ Sein Eindruck ist außerdem, dass Konsumentinnen und Konsumenten sich selten mit den Risiken der Substanz auseinandersetzen: “Unsere Wahrnehmung ist, dass tatsächlich viele Menschen da sehr unbedarft rangehen. Das heißt, das wirklich anders einschätzen als andere Substanzen“. Es gehe Konsumierenden häufig um die euphorisierende Wirkung von Kokain: “Da geht’s viel um intensive Spaßerfahrung, also Hochgefühle, auch darum einen Ausgleich zu schaffen zu Frustration und Stress im Alltag. Das beobachten wir generell hier auch in vielen Beratungsgesprächen, dass ein hoher Leistungsdruck besteht.“

In NRW sind die Kokain- und Crack-Delikte aktuell auf einem Rekordniveau.

Nach Angaben der Polizeilichen Kriminalstatistik, die im April 2026 veröffentlicht wurde, erfasste die Polizei 2025 rund 7.500 entsprechende Straftaten. Das sind dreimal so viele wie zehn Jahre zuvor.

Die Statistik erfasst allerdings nur bekannt gewordene Fälle. Ob es später zu einer Verurteilung kommt, geht aus den Zahlen nicht hervor. Eine Steigerung der Straftaten kann auch auf intensivere Kontrollen und Ermittlungen zurückzuführen sein.

Unter den rund 7.500 erfassten Delikten im Zusammenhang mit Kokain und Crack werden unterschiedliche Straftaten zusammengefasst, dazu zählen Besitz, sowie Handel, Herstellung und Schmuggel.

Von 2022 auf 2023 gab es den deutlichsten Anstieg der Kokain-Delikte: innerhalb eines Jahres sind die Straftaten um 25% gestiegen.

Nach Angaben des Landeskriminalamts in NRW hat die Entwicklung mehrere Gründe: Zum einen kontrolliere die Polizei verstärkt. Zum anderen sei Kokain zunehmend verfügbar.

1LIVE Themenwoche vom 31.August bis 3. September

Auf Basis der 1LIVE Datenerhebung wird im 1LIVE Radioprogramm, auf den 1LIVE Social Media Kanälen, sowie in der 1LIVE App und auf 1LIVE.de erzählt, wie sich Kokainkonsum entwickelt hat, wieso Kokain besonders für junge Menschen ein großes Thema ist.

Auf 1LIVE.de ist ab dem 31.August um 5:00 Uhr die gesamte Recherche mit Grafiken und Erklärungen verfügbar.

Pressekontakt:

Programmbereich Aktuelles

WDR Newsroom

Elstergasse 1

50667 Köln

Telefon +49 (0)221 220-8787

E-Mail: newsroom-jetzt@wdr.de

Original-Content von: WDR Newsroom, übermittelt durch news aktuell

Growing Sportcation Travel Trend: Trip.com Group Reports 40% Increase in Active Travel Booking GMV

NEWS PROVIDED BY

Trip.com Group

Aug 30, 2026, 23:39 ET

SHARE THIS ARTICLE

SINGAPORE, Aug. 30, 2026 /PRNewswire/ -- Active travel or 'sportcations' are becoming the next big travel trend, with Trip.com Group seeing a strong double-digit increase in booking GMV. From cycling through mountain passes to joining diving camps and wellness retreats, active travel is becoming a defining part of how people experience the world.

A growing passion for active travel

This shift is gathering pace across the full travel journey, with searches for active sports experiences growing by over 30% year on year, with markets witnessing substantial increases: 80% in Singapore, 65% in Malaysia, and 50% in the United Kingdom, while France, Italy, Germany, and Spain all recorded triple-digit growth.

Total travel booking GMV has increased by almost 40%, with markets such as South Korea (+150%), Singapore (+104%), and Thailand (+200%) seeing bookings more than double over the past year. The same is seen for European travellers. The United Kingdom saw bookings grow by over 100%, and Germany by over 600%, highlighting that travellers are increasingly planning holidays around experiences that get them moving.

From adrenaline to adventure, travellers are following their passions

Active travel is taking many forms, reflecting the wide range of interests shaping today's holidays. Globally, diving ranks as the most-booked sporting experience, followed by activities such as ziplining, paragliding, skydiving and cycling.

Across individual markets, preferences vary, giving destinations their own unique sporting identities. Adventure activities prove especially popular across Asia. Diving leads bookings in South Korea, Malaysia, Germany, Spain, Italy and France. At the same time, skydiving ranks first in Hong Kong, Taiwan and Thailand, while Japanese travellers show the strongest preference for cycling.

Destinations are driving signature experiences

As travellers increasingly build holidays around the activities they love, certain places are emerging as go-to destinations for particular passions. The data shows that five destinations in particular stand out across multiple types of active travel, with Thailand, China, Australia, New Zealand and Malaysia appearing among the leading destinations across cycling, climbing, swimming, water sports and adventure experiences.

Thailand leads the way, appearing across all five categories and ranking as the leading destination for diving, while also featuring among the top destinations for cycling, water sports and adventure activities. This breadth of experiences makes it a particularly strong destination for travellers looking to combine different activities within one trip.

Australia stands out as another versatile destination, attracting travellers for cycling, rock climbing, surfing and kayaking, as well as adventure activities such as paragliding and skydiving. Its presence across multiple categories reflects the growing appeal of destinations where travellers can combine diverse active experiences within the same holiday.

From travelling together to inspiring others

While the passion for active experiences is shared globally, the way people travel differs across regions. In Europe, the average travel party is 1-2 people, suggesting many travellers are embarking on solo adventures or trips with a partner. Across the Asia-Pacific region, the average group size increases to 2-3, highlighting the popularity of travelling with friends and family to share new experiences.

These experiences are also shaping how travellers engage online. Active travel-related posts on Trip.Moments have nearly doubled globally, growing by 99% year on year as more travellers document their adventures and inspire others to follow in their footsteps. Several markets have seen particularly strong growth in community sharing, including Spain (224.9%), the United Kingdom (122.2%), Italy (118.9%), China (96.2%) and France (86.9%), reflecting the growing popularity of active travel across both Asia and Europe.

The conversations are becoming more engaging, too. While the number of posts has nearly doubled, comments have grown twelvefold compared with the previous year, demonstrating that active travel is encouraging richer conversations rather than simply more content. From destination tips to training advice and first-hand recommendations, travellers are helping one another discover their next active escape, creating a cycle where inspiration leads to bookings and every journey inspires the next.

As travellers continue looking for more meaningful ways to explore the world, active travel is evolving from a niche interest into a mainstream travel trend. Whether it is mastering a new skill, training for a personal goal or simply enjoying the outdoors, active experiences are helping people build stronger connections with destinations and with each other.

About Trip.com Group

Trip.com Group is a global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group is on the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com.

Follow us on: X, Facebook, LinkedIn, and YouTube.

SOURCE Trip.com Group

21%

more press release views with 

Request a Demo

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management USA - English

NEWS PROVIDED BY

Huawei

Aug 30, 2026, 23:42 ET

SHARE THIS ARTICLE

MUNICH, Aug. 30, 2026 /PRNewswire/ -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and fitness, offering an exclusive sneak peek at its next-generation ambulatory blood pressure monitor, the HUAWEI WATCH D3, ahead of its official launch at the Huawei Innovative Product Launch in Munich on 2 September. Bridging cutting-edge academic research with everyday consumer technology, Huawei continues to demonstrate its commitment to open collaboration, connecting pioneering research with products that reshape people's daily lives.

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026

A Legacy of Persistence, A Leap Forward

Huawei's journey in blood pressure monitoring technology traces back to 2014, when the company first ventured into the sports and health domain. Over the past decade, Huawei has steadily advanced wearable health monitoring technologies to drive the evolution of the industry, from dynamic heart rate monitoring and SpO₂ tracking to ECG collection, and ultimately to blood pressure measurement.

In 2021, Huawei launched its first wrist-based ambulatory blood pressure recorder, the HUAWEI WATCH D. This device brought medical-grade blood pressure measurement capabilities to people's wrists for the first time, securing medical device certification in multiple countries and regions, including China and the European Union. In 2024, the HUAWEI WATCH D2 was officially released, introducing 24-hour ambulatory blood pressure monitoring and redefining blood pressure management.

In 2026, Huawei is set to unveil its latest achievement in blood pressure health—the next-generation HUAWEI WATCH D series. As the latest wrist-based ambulatory blood pressure recorder, the HUAWEI WATCH D3 achieves further breakthroughs across more blood pressure measurement scenarios while delivering more comprehensive health protection.

Lightweight Design, Professionalism Meets Style

To enhance comfort during extended wear, the HUAWEI WATCH D3 features further refinements in device thickness and strap weight. It will be available in three fashionable colour options inspired by "nature's healing"—designed not only for comfort but also as a stylish everyday accessory, seamlessly blending in with diverse lifestyles and sports scenarios.

Broader Scenarios, Richer Health Insights

The HUAWEI WATCH D3 ensures accurate blood pressure measurement at elevated heart rates. It accurately records blood pressure data before and after exercise, provides recommendations on appropriate exercise intensity, and helps users develop good fitness habits. Furthermore, the HUAWEI WATCH D3 has been certified by CE MDR in the European Union, with its certification scope covering single blood pressure measurements, ambulatory blood pressure monitoring, and pre- and post-exercise blood pressure measurements. Newly added features include blood pressure measurement reminders for high-altitude environments and sudden temperature changes, ensuring users never miss a critical monitoring check.

Beyond its core blood pressure monitoring capabilities, the HUAWEI WATCH D3 also offers richer Health Glance metrics and health studies, alongside continuous improvements in sleep and emotional wellbeing tracking[1]. Further details on specific applications will be announced in due course.

Stay tuned to Huawei's official channels for information on the official launch date, pricing, and full specifications of the HUAWEI WATCH D3.

[1] The data collected by Health Glance features and health studies is for reference only, and should not be used for diagnosis or treatment.

SOURCE Huawei

21%

more press release views with 

Request a Demo

Ranking First in Global Sales for Ten Consecutive Years, LGMG's Wide-Body Mining Trucks Lead the World's Mine Transport Equipment Sector

NEWS PROVIDED BY

LGMG

Aug 30, 2026, 23:44 ET

SHARE THIS ARTICLE

JINAN, China, Aug. 30, 2026 /PRNewswire/ -- Recently, the globally renowned growth consulting company Frost & Sullivan officially released the 2026 Independent Market Research Report on Global Off-Highway Mechanical Drive Wide-Body Dump Trucks. Based on rigorous data tracking and analysis of the global market from 2016 to 2025—a full decade—the report formally confirms that LGMG has ranked first in global sales of off-highway mechanical drive wide-body dump trucks for ten consecutive years. This milestone certification signifies that Chinese mining equipment manufacturers continue to lead in the global premium market. It further validates LGMG's deep accumulation in technological innovation, product quality, and global expansion.

A Highly Concentrated Market: The Strong Prevail.

Off-highway mechanical drive wide-body dump trucks refer to self-unloading trucks that operate in off-highway conditions and are specially designed for earthmoving, rock, and mineral transport in complex environments such as mines and large-scale construction projects. With a load capacity typically ranging from 40 to 150 tons, these trucks feature wide bodies, robust frames, and excellent stability, making them indispensable core transport equipment in open-pit mining operations.

Currently, there are 15 to 20 relevant enterprises in this industry globally, and the market presents a highly concentrated competitive landscape. Industry leaders include Chinese companies such as LGMG, TONLY, XCMG, and SANY, while also facing competition from international giants like Komatsu and Caterpillar. In such fierce global competition, LGMG's ability to maintain the top sales position for ten consecutive years fully demonstrates its comprehensive advantages in product technology, manufacturing capabilities, market channels, and customer service.

Innovation-Driven – A Leap from Follower to Leader

Founded in 2012, LGMG is a globally leading enterprise in mining equipment, aerial work platforms and material handling machinery, committed to providing intelligent, efficient, and green solutions to global customers through continuous innovation and technology. The company specializes in the R&D, design, manufacturing, sales, and service of machinery equipment in the fields of mining, aerial work, and material handling.

In terms of technological innovation, LGMG has always been at the forefront of the industry. The company has not only developed electronically controlled mining excavators but has also formed deep partnerships with multiple autonomous driving and new energy emerging manufacturers, taking the lead in achieving commercial-scale applications of autonomous and new-energy mining equipment at multiple mine sites. This has given the company a first-mover advantage in the industrial transformation toward electrification and intelligentization of mining equipment.

In terms of product portfolio, LGMG has established a comprehensive range of wide-body mining trucks covering 40-ton, 60-ton, 100-ton, and larger tonnage classes, with a gradual extension into new-energy variants, capable of meeting diverse transportation needs across various working conditions. In terms of global expansion, the company's sales footprint now covers more than 100 countries and regions worldwide, occupying significant positions in key markets across Asia, Europe, Africa, and the Americas. Through a well-established overseas sales and service network, LGMG provides timely and professional technical support and after-sales services to global customers.

Looking Ahead – Leading the New Era of Green and Intelligent Mining

Currently, the global off-highway mechanical drive wide-body dump truck industry is undergoing profound transformation. With increasing global requirements for green and low-carbon development, new-energy wide-body dump trucks are gradually becoming the industry's direction. Autonomous driving, remote control, intelligent dispatching, and other technologies are being rapidly implemented in mine transport. Additionally, large tonnage, high load capacity, and high reliability have become major industry trends.

Building on ten consecutive years of global sales leadership, LGMG will continue to uphold its innovation-driven development philosophy, deepen its presence in the mining equipment sector, accelerate the R&D and industrialization of new-energy and intelligent products, and further enhance its global market competitiveness. The company is committed to creating greater value for mining customers worldwide and contributing to the high-quality development of China's mining equipment manufacturing industry and the green and low-carbon transformation of the global mining sector.

Ten consecutive years mark not an end, but the beginning of a new journey. LGMG, as a pacesetter, is steadily advancing toward its goal of becoming a world-class mining equipment enterprise.

SOURCE LGMG

21%

more press release views with 

Request a Demo